NeuroRx
  • Home
  • About Us
  • Covid-19
  • NRX-100/101
  • News
  • Contact
  • Home
  • News

News

Press releases

Relief Therapeutics and NeuroRx Expand Clinical Trial Evaluating RLF-100 in Critically Ill COVID-19 Patients with Respiratory Failure to Houston Methodist Hospital

Clinical trial expanded to patients treated with both noninvasive and mechanical ventilation in Critical COVID-19.

Read more
Press releases

Relief Therapeutics and NeuroRx Expand Clinical Trial of RLF-100 to All Patients with Critical COVID-19 and Respiratory Failure

Clinical trial expanded to patients treated with both noninvasive and mechanical ventilation in critical COVID-19.

Read more
Press releases

Relief Therapeutics and NeuroRx Announce Enrollment of First Patients with RLF-100 in Phase 2b/3 Clinical Trial in Patients with COVID-19 Associated Acute Respiratory Distress

First participants treated at the University of Miami Miller School of Medicine with intravenous RLF-100.

Read more
News

UCI to take part in clinical trial of drug for critically ill COVID-19 patients

“If successful, we hope that treatments such as Aviptadil may change the chances of survival for these patients,” says Dr. Richard Lee, who is leading the trial at UCI. Carlos Puma for UCI Health”

Read more
Broadcasts

UM Hospital Testing New Treatment For Patients Suffering The Worst Of COVID-19

https://www.youtube.com/watch?v=ztSFZlavXU0&feature=youtu.be
Read more
Broadcasts

FDA advances Covid-19 therapy-Prof. Jonathan Javitt

https://www.youtube.com/watch?v=lgmpS2N8124
Read more
News

Relief Therapeutics, NeuroRx get FDA nod to start coronavirus trial Thompson Reuters

Thompson Reuters TEL AVIV, March 29 (Reuters) – The U.S. Food & Drug Administration has authorised the start of a mid-stage trial by U.S.-Israeli NeuroRx and Relief Therapeutics for the use of Aviptadil to treat Acute Respiratory Distress in coronavirus patients. The companies said on Sunday they are recruiting study sites and pharmacies to begin […]

Read more
Press releases

NeuroRx to discuss investigational drug for COVID-19 related Acute Respiratory Distress at Solebury Trout Virtual Global Healthcare Conference on March 26, 2020

NeuroRx is leading US development of RLF-100 (Aviptadil) on behalf of Relief Therapeutics’ (RLF).

Read more
  • 1
  • 2
  • 3

Categories

  • Broadcasts
  • News
  • Press releases

Tags

Accelerated Recovery ARDS Aviptadil BARDA Big Rock Partners Bipolar Depression Clinical Trials Covid-19 Critical COVID-19 Emergency Use Expanded Access Fast Track FDA High Flow Nasal Houston I-Spy i24 News NASDAQ NRX-100/101 NRXP Orphan Drug Designation Respiratory Failure RLF-100 RLF-100_002 Sever COVID-19 UCI VIP ZYESAMI Zysami

Developing innovative therapies for high-mortality unmet needs.

Company Info

  • About Us
  • RLF-100
  • NRX 100/101

Learn More

  • USA-Licensed Physicians
  • Investors
© 2020 NeuroRx, Inc.